TLDR
- Zymeworks’ stock jumps 33% on groundbreaking HER2+ cancer drug results.
- Zymeworks sees a 33% surge after Phase 3 trial success for Ziihera.
- Zymeworks’ Ziihera shows major promise, boosting stock by 33%.
- Positive cancer trial results push Zymeworks’ stock up 33%.
- Zymeworks shares soar 33% on strong HER2+ cancer drug trial outcomes.
Zymeworks Inc.(ZYME) saw a significant surge in its stock price, rising by 33.09% to $24.65 as of 10:50 AM EST.
Zymeworks Inc., ZYME
This dramatic jump followed the company’s announcement of positive topline results from its Phase 3 HERIZON-GEA-01 trial. The trial evaluated Ziihera® (zanidatamab-hrii) in combination with chemotherapy, showing strong efficacy in treating HER2-positive gastroesophageal adenocarcinoma (GEA), a cancer with limited treatment options.
Positive Trial Results for Ziihera in HER2+ Cancer Treatment
ZYME reported highly promising results from the HERIZON-GEA-01 trial, which focused on HER2-positive cancers of the stomach, gastroesophageal junction, and esophagus. Both the Ziihera plus chemotherapy and Ziihera plus chemotherapy with the PD-1 inhibitor Tevimbra (tislelizumab) arms showed statistically significant improvements in progression-free survival (PFS). Ziihera, in combination with Tevimbra, also demonstrated notable overall survival (OS) improvements. These results far surpassed the control arm, which used trastuzumab with chemotherapy.
The trial provided critical data that suggests Ziihera could offer a new, effective treatment option for HER2-positive GEA. Both primary and secondary endpoints of the trial were achieved, with significant gains observed in objective response rates (ORR) and duration of response (DoR). The results, presented today by Zymeworks’ partners Jazz Pharmaceuticals and BeOne Medicines, mark a turning point for patients with this hard-to-treat cancer. ZYME is optimistic about the potential of its drug, with an additional planned OS interim analysis set for mid-2026.
Zymeworks’ Strategic Partnerships Strengthen Its Position
The success of the HERIZON-GEA-01 trial highlights Zymeworks’ growing strategic importance in the oncology sector. Jazz Pharmaceuticals and BeOne Medicines play a crucial role in the development and commercialization of Ziihera. ZYME, under its partnership agreements, will receive significant milestone payments and tiered royalties on Ziihera’s sales. The company also anticipates submitting the trial data for presentation at a major medical meeting in 2026 and for publication in a peer-reviewed journal.
ZYME is well-positioned to accelerate Ziihera’s development and adoption in the treatment of HER2-positive cancers. The FDA has already granted Breakthrough Therapy and Fast Track designations for Ziihera in other indications, adding to its credibility and potential in the oncology market. It aims to submit a supplemental Biologics License Application in 2026, marking a critical step toward making Ziihera a standard part of treatment regimens for advanced GEA.
The combination of successful clinical trials and strong partnerships has made Zymeworks a key player in the biopharmaceutical industry. With Ziihera showing promising results in multiple trials, the company is on track to significantly impact the treatment landscape for cancer patients.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
